Stellate Ganglion Block
Conditions
Brief summary
Stellate Ganglion Block as Novel Treatment for Heart Failure Patients
Detailed description
Stellate Ganglion Block as Novel Treatment for Heart Failure Patients
Interventions
PROCEDUREStellate Ganglion Block
A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
Sponsors
Mina sobhi said fam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 : 70 years old. * NYHA Class III-IV Heart Failure. * Heart failure with a reduced ejection fraction (HFrEF) LVEF ≤ 40% calculated using 2D echocardiography and Biplane Simpson's . * Optimal tolerated Medical Therapy for Heart Failure.
Exclusion criteria
* Active Malignancy. * Acute heart failure including pulmonary edema or cardiogenic shock. * Severe, life-threatening non-cardiac disease. * Pregnancy. * Localized infection. * Coagulopathy or anticoagulated patients. * Refused this procedure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of left ventricular ejection fraction (LVEF). | 3 month | Change of left ventricular ejection fraction (LVEF). |
| Change of NYHA classification. | 3 month | Change of NYHA classification. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of 6 minutes walking test. | 3 month | Change of 6 minutes walking test. |
| Heart failure hospitalization. | 3 month | Heart failure hospitalization. |
| Vascular complications and safety issues. | 3 month | Vascular complications and safety issues. |
| Cardiovascular death. | 3 month | Cardiovascular death. |
Countries
Egypt
Contacts
Primary ContactMina Fam, Resident
Backup ContactAly Tohamy, Lecturer
Outcome results
None listed